The global lennox-gastaut syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Lennox-Gastaut syndrome (LGS) is a type of epilepsy that is characterized by frequent and usually daily seizures. The major factor for the growth of the market is the increasing prevalence of LSG across the globe. According to the National Organization for Rare Disorders (NORD), LSG affects males more often than females. It is estimated to occur in .1-.28 people per 100,000. Additionally, it is estimated that it accounts for 1-4% of all cases of childhood epilepsy. Furthermore, it is estimated to occur in 2 per 100,000 children annually. Moreover, it usually occurs between 2-7 years with a peak onset between 3 to 5 years. Hence, the rising prevalence of the disease is driving the demand for LSG drugs which in turn is driving the growth of the market. 

Some major players operating in the market include Johnson & Johnson Services, Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2021, Glenmark Pharma announced the launch of the anti-epileptic drug Rufinamide tablets in the US market. Rufinamide tablets are the therapeutic equivalent of Banzel tablets of Eisai, Inc. that is used for the treatment of children with Lennox-Gastaut syndrome.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Type

o By Therapy

o By Route of Administration

o By Distribution Channel

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Johnson & Johnson Services, Inc., and Novartis International AG, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Lennox-Gastaut Syndrome Drug Market Report by Segment

By Drug Type 

    • CNS depressants

    • Anticonvulsants

    • Perampanel

    • Cannabidiol

    • NRP-2945

    • Others

By Therapy 

    • Medication

    • Surgery

    • Intravenous Immunoglobulin Therapy

    • Ketogenic Diet Products

By Distribution Channel 

    • Hospital Pharmacy

    • Retail Pharmacy

    • Online Pharmacy

Global Lennox-Gastaut Syndrome Drug Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa